Abstract
Background Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE, but only half of patients show a response to it. While some of the patients that do not initially respond to HCQ benefit from the addition of QC, there is a subset of patients that are refractory to both antimalarials. Refractoriness poses a huge challenge because these patients will often continue to have active disease when they are initially started on antimalarials. To better characterize these refractory patients, we investigated the immunologic characteristics of patients that respond to antimalarials versus those that do not. Methods CLE patients were classified as HCQ-responders, HCQ/QC-responders, or HCQ/QC-nonresponders. Immunohistochemistry was used to characterize the inflammatory cell composition and cytokine expression in lesional skin biopsies from patients. Total RNA was extracted from these biopsies to analyze specific gene signatures. The patient’s CLASI score – a measure of disease activity – at the time of the biopsy was also determined. Results Immunohistochemistry showed that myeloid dendritic cells (mDCs) were significantly higher in HCQ/QC-responders compared to HCQ-responders and HCQ/QC-nonresponders, while plasmacytoid dendritic cells, neutrophils, macrophages, and autoreactive T cells did not differ significantly among the three groups. The HCQ/QC-nonresponder group was distinct from the other groups in that their CLASI scores did correlate positively with the number of macrophages (p Conclusions An increased number of mDCs may contribute to HCQ-refractoriness and predict a better response to treatment with both HCQ and QC but do not contribute to HCQ/QC-refractoriness. The significant correlation between macrophages and CLASI scores in the HCQ/QC-nonresponders, a finding not seen in either HCQ or HCQ/QC-responders, may also indicate that macrophages are more involved in antimalarial-refractory skin disease. The difference between the responders and nonresponders is further confirmed by the cytokine staining and mRNA expression. Our data is an initial step in determining the activation pathways that account for the lack of response to antimalarials. Acknowledgements This work was supported by National Institutes of Health [K24 AR002207] and Veterans Affairs Merit Review [I01B × 000706] to Dr. Victoria Werth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.